Fluvoxamine in the Treatment of Patients with COVID-19

{ 'indexed': {'date-parts': [[2022, 4, 2]], 'date-time': '2022-04-02T05:29:54Z', 'timestamp': 1648877394484}, 'reference-count': 25, 'publisher': 'Professionals Publications', 'issue': '2', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2021, 6, 4]]}, 'abstract': '<jats:p>Наряду с легкими и другими внутренними органами COVID-19 поражает и центральную ' 'нервную систему. Воспалительные реакции, секреция цитокинов в головном мозге вызывают у ' 'большинства пациентов тревожные и депрессивные симптомы, нарушения сна. Психические ' 'расстройства связаны и с психосоциальными факторами пандемии. Для купирования ' 'психопатологических симптомов при COVID-19 часто используются антидепрессанты из группы ' 'селективных ингибиторов обратного захвата серотонина. Среди них особое место занимает ' 'флувоксамин. Флувоксамин помимо антидепрессивных и противотревожных эффектов проявляет четкие ' 'противовоспалительные свойства, которые реализуются посредством двух механизмов. Флувоксамин ' 'существенно повышает уровень ночного мелатонина в плазме крови. Мелатонин оказывает ' 'противовоспалительное, антиоксидантное и нормализующее хронобиологическое действие. Второй ' 'механизм связан с тем, что флувоксамин в терапевтических дозировках активирует сигма-1 ' 'рецепторы, что предупреждает секрецию цитокинов и развитие эндоплазматического стресса. ' 'Пациенты с COVID-19, принимавшие флувоксамин, не отмечали клинических осложнений ' 'коронавирусной инфекции.</jats:p>\n' ' ' '<jats:p>COVID-19 affects central nervous system along with lungs and other internal organs. ' 'Inflammatory reactions, secretion of cytokines in brain cause anxiety and depressive ' 'symptoms, sleep disturbances in most patients. Mental disorders are also associated with ' 'psychosocial factors of the pandemic. SSRI antidepressants are often used to relieve ' 'psychopathological symptoms in COVID-19. Among them, fluvoxamine occupies a special place. ' 'Fluvoxamine, in addition to antidepressant and anti-anxiety effects, exhibits clear ' 'anti-inflammatory properties, which are realized through two mechanisms. Fluvoxamine ' 'significantly increases the level of nocturnal melatonin in blood plasma. Melatonin has ' 'anti-inflammatory, antioxidant and chronobiological normalizing effects. The second mechanism ' 'is associated with the fact that fluvoxamine in therapeutic dosages activates sigma-1 ' 'receptors, which prevents secretion of cytokines and development of endoplasmic stress. ' 'Patients with COVID-19 taking fluvoxamine did not report clinical complications of ' 'coronavirus infection.</jats:p>', 'DOI': '10.34883/pi.2021.12.2.007', 'type': 'journal-article', 'created': {'date-parts': [[2022, 2, 24]], 'date-time': '2022-02-24T10:40:46Z', 'timestamp': 1645699246000}, 'page': '260-268', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Fluvoxamine in the Treatment of Patients with COVID-19', 'prefix': '10.34883', 'author': [{'given': 'М.А.', 'family': 'Ассанович', 'sequence': 'first', 'affiliation': []}], 'member': '34055', 'reference': [ { 'key': '1', 'doi-asserted-by': 'crossref', 'unstructured': 'Cullen W., Gulati G., Kelly B.D. (2020) Mental health in the COVID-19 ' 'pandemic. QJM : monthly journal of the Association of Physicians, vol. ' '113, no 5, pp. 311–312.', 'DOI': '10.1093/qjmed/hcaa110'}, { 'key': '2', 'doi-asserted-by': 'crossref', 'unstructured': 'Orsini A., Corsi M., Santangelo A., Riva A. (2020) Challenges and ' 'management of neurological and psychiatric manifestations in SARS-CoV-2 ' '(COVID-19) patients. Neurological Sciences, vol. 41, pp. 2353–2366.', 'DOI': '10.1007/s10072-020-04544-w'}, { 'key': '3', 'doi-asserted-by': 'crossref', 'unstructured': 'Bouças A.P., Rheinheimer J., Lagopoulos J. (2020) Why Severe COVID-19 ' 'Patients Are at Greater Risk of Developing Depression: A Molecular ' 'Perspective. Neuroscientist (electronic journal). Available at: ' 'https://journals.sagepub.com/doi/10.1177/1073858420967892?url_ver=Z39.88- ' '2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200pubmed ' '(accesed 5 May 2021).', 'DOI': '10.1177/1073858420967892'}, { 'key': '4', 'doi-asserted-by': 'crossref', 'unstructured': 'Schiepers O.J.G., Wichers M.C., Maes M. (2005) Cytokines and major ' 'depression. Progress in Neuro-Psychopharmacology and Biological ' 'Psychiatry, vol. 29, pp. 201–217.', 'DOI': '10.1016/j.pnpbp.2004.11.003'}, { 'key': '5', 'doi-asserted-by': 'crossref', 'unstructured': 'Villoutreix B.O., Beaune P.H., Tamouza R. (2020) Prevention of COVID-19 ' 'by drug repurposing: rationale from drugs prescribed for mental ' 'disorders. Drug Discovery Today, vol. 25, pp.1287–1290.', 'DOI': '10.1016/j.drudis.2020.06.022'}, { 'key': '6', 'doi-asserted-by': 'crossref', 'unstructured': 'Lemaitre F., Solas C., Grégoire M. (2020) Potential drug–drug ' 'interactions associated with drugs currently proposed for COVID-19 ' 'treatment in patients receiving other treatments. Fundamental and ' 'Clinical Pharmacology, vol. 34, pp. 530–547.', 'DOI': '10.1111/fcp.12586'}, { 'key': '7', 'doi-asserted-by': 'crossref', 'unstructured': 'Bishara D., Kalafatis C., Taylor D. (2020) Emerging and experimental ' 'treatments for COVID-19 and drug interactions with psychotropic agents. ' 'Therapeutic Advances in Psychopharmacology (electronic journal), vol. ' '10. Available at: https://journals.sagepub.com/doi/ ' 'full/10.1177/2045125320935306 (Accessed 5 May 2021).', 'DOI': '10.1177/2045125320935306'}, { 'key': '8', 'doi-asserted-by': 'crossref', 'unstructured': 'Zhang K., Zhou X., Liu H. (2021) Treatment concerns for psychiatric ' 'symptoms in patients with COVID-19 with or without psychiatric ' 'disorders. British Journal of Psychiatry, vol. 217, pp. 351.', 'DOI': '10.1192/bjp.2020.84'}, { 'key': '9', 'doi-asserted-by': 'crossref', 'unstructured': 'Hashimoto K. (2021) Repurposing of CNS drugs to treat COVID-19 ' 'infection: targeting the sigma-1 receptor. European Archives of ' 'Psychiatry and Clinical Neuroscience, vol. 271, pp. 249–258.', 'DOI': '10.1007/s00406-020-01231-x'}, { 'key': '10', 'doi-asserted-by': 'crossref', 'unstructured': 'Rohilla J., Tak P., Jhanwar S. (2020) Primary care physician’s approach ' 'for mental health impact of COVID-19. Journal of Family Medicine and ' 'Primary Care (electronic journal), vol. 9. Available at: ' 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567264/ (Accessed 5 May ' '2021).', 'DOI': '10.4103/jfmpc.jfmpc_513_20'}, { 'key': '11', 'doi-asserted-by': 'crossref', 'unstructured': 'Park E.J., Lee J.H., Jeong D.C. (2015) Natural killer cell activity in ' 'patients with major depressive disorder treated with escitalopram. ' 'International Immunopharmacology, vol. 28, pp. 409–413.', 'DOI': '10.1016/j.intimp.2015.06.031'}, { 'key': '12', 'doi-asserted-by': 'crossref', 'unstructured': 'Omori I.M., Watanabe N., Nakagawa A. (2010) Fluvoxamine versus other ' 'anti-depressive agents for depression. Cochrane Database of Systematic ' 'Reviews. Available at: ' 'https://www.cochrane.org/CD006114/DEPRESSN_fluvoxamine-versus-other-anti-depressive-agents-for- ' 'depression#:~:text=Fluvoxamine versus other anti-depressive agents for ' 'depression Major,symptoms%2C inappropriate guilt and morbid thoughts of ' 'death (Accessed 5 May 2021).', 'DOI': '10.1002/14651858.CD006114.pub2'}, { 'key': '13', 'unstructured': 'Irons J. (2005) Fluvoxamine in the treatment of anxiety disorders. ' 'Neuropsychiatric disease and treatment, vol. 1, pp. 289–299.'}, { 'key': '14', 'doi-asserted-by': 'crossref', 'unstructured': 'Zhang R., Wang X., Ni L. (2020) COVID-19: Melatonin as a potential ' 'adjuvant treatment. Life Sciences (electronic journal). Available at: ' 'https://www. sciencedirect.com/science/article/abs/pii/S0024320520303313 ' '(Accessed 5 May 2021).', 'DOI': '10.1016/j.lfs.2020.117583'}, { 'key': '15', 'doi-asserted-by': 'crossref', 'unstructured': 'Shneider A., Kudriavtsev A., Vakhrusheva A. (2020) Can melatonin reduce ' 'the severity of COVID-19 pandemic? International Reviews of Immunology, ' 'vol. 39, pp. 153–162.', 'DOI': '10.1080/08830185.2020.1756284'}, { 'key': '16', 'doi-asserted-by': 'crossref', 'unstructured': 'Acuña-Castroviejo D., Escames G., Figueira J.C. (2020) Clinical trial to ' 'test the efficacy of melatonin in COVID-19. Journal of Pineal Research, ' 'vol. 69, pp. 1–4.', 'DOI': '10.1111/jpi.12683'}, { 'key': '17', 'doi-asserted-by': 'crossref', 'unstructured': 'Reiter R.J., Abreu-Gonzalez P., Marik P.E. (2020) Therapeutic Algorithm ' 'for Use of Melatonin in Patients With COVID-19. Frontiers in Medicine, ' 'vol. 7. Available at: ' 'https://www.frontiersin.org/articles/10.3389/fmed.2020.00226/full ' '(Accessed 5 May 2021).', 'DOI': '10.3389/fmed.2020.00226'}, { 'key': '18', 'doi-asserted-by': 'crossref', 'unstructured': 'Von Bahr C., Ursing C., Yasui N. (2000) Fluvoxamine but not citalopram ' 'increases serum melatonin in healthy subjects – An indication that ' 'cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin. European ' 'Journal of Clinical Pharmacology, vol. 56, pp. 123–127.', 'DOI': '10.1007/s002280050729'}, { 'key': '19', 'doi-asserted-by': 'crossref', 'unstructured': 'Anderson G.M. (2021) Fluvoxamine, melatonin and COVID-19. ' 'Psychopharmacology, vol. 238, no 2, pp. 611.', 'DOI': '10.1007/s00213-020-05753-z'}, { 'key': '20', 'doi-asserted-by': 'crossref', 'unstructured': 'Dallé E., Daniels W.M.U., Mabandla M V. (2017) Fluvoxamine maleate ' 'normalizes striatal neuronal inflammatory cytokine activity in a ' 'Parkinsonian rat model associated with depression. Behavioural Brain ' 'Research, vol. 316, pp. 189–196.', 'DOI': '10.1016/j.bbr.2016.08.005'}, { 'key': '21', 'doi-asserted-by': 'crossref', 'unstructured': 'Yoshimura R., Katsuki A., Atake K. (2017) Influence of fluvoxamine on ' 'plasma interleukin-6 or clinical improvement in patients with major ' 'depressive disorder. Neuropsychiatric Disease and Treatment, vol. 13, ' 'pp. 437–441.', 'DOI': '10.2147/NDT.S123121'}, { 'key': '22', 'doi-asserted-by': 'crossref', 'unstructured': 'Troncone L.R. (2020) COVID-19, cytokine storm and sigma-1 receptors: ' 'potential treatments at hand? Authorea, vol. 19, pp. 1–3.', 'DOI': '10.22541/au.159335613.31156244'}, { 'key': '23', 'doi-asserted-by': 'crossref', 'unstructured': 'Hindmarch I., Hashimoto K. (2010) Cognition and depression: The effects ' 'of fluvoxamine, a sigma-1 receptor agonist, reconsidered. Human ' 'Psychopharmacology, vol. 25, pp. 193–200.', 'DOI': '10.1002/hup.1106'}, { 'key': '24', 'doi-asserted-by': 'crossref', 'unstructured': 'Lenze E.J., Mattar C., Zorumski C.F. (2020) Fluvoxamine vs Placebo and ' 'Clinical Deterioration in Outpatients with Symptomatic COVID-19: A ' 'Randomized Clinical Trial. Journal of the American Medical Association, ' 'vol. 324, pp. 2292–2300.', 'DOI': '10.1001/jama.2020.22760'}, { 'key': '25', 'doi-asserted-by': 'crossref', 'unstructured': 'Seftel D., Boulware D.R. (2021) Prospective Cohort of Fluvoxamine for ' 'Early Treatment of Coronavirus Disease 19. Open Forum Infectious ' 'Diseases, vol. 8, pp. 1–3.', 'DOI': '10.1093/ofid/ofab050'}], 'container-title': 'Психиатрия, психотерапия и клиническая психология', 'original-title': ['Флувоксамин в терапии пациентов с COVID-19'], 'language': 'ru', 'deposited': { 'date-parts': [[2022, 2, 24]], 'date-time': '2022-02-24T10:42:00Z', 'timestamp': 1645699320000}, 'score': 1, 'resource': { 'primary': { 'URL': 'https://psihea.recipe.by/ru/?editions=2021-tom-12-n-2&group_id=item_1&article_id=line_1'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 6, 4]]}, 'references-count': 25, 'journal-issue': {'issue': '2', 'published-print': {'date-parts': [[2021, 6, 4]]}}, 'URL': 'http://dx.doi.org/10.34883/PI.2021.12.2.007', 'relation': {}, 'ISSN': ['2220-1122', '2414-2212'], 'subject': [], 'published': {'date-parts': [[2021, 6, 4]]}}